as 11-14-2024 10:32am EST
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Founded: | 2022 | Country: | United States |
Employees: | N/A | City: | PONTE VEDRA |
Market Cap: | 26.3M | IPO Year: | 2023 |
Target Price: | $46.00 | AVG Volume (30 days): | 85.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -7.07 | EPS Growth: | N/A |
52 Week Low/High: | $5.40 - $32.55 | Next Earning Date: | 11-07-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
CVKD Breaking Stock News: Dive into CVKD Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
PR Newswire
7 days ago
PR Newswire
13 days ago
Simply Wall St.
17 days ago
PR Newswire
21 days ago
PR Newswire
22 days ago
PR Newswire
2 months ago
Zacks Small Cap Research
2 months ago
The information presented on this page, "CVKD Cadrenal Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.